Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
- Dosed first patient with HPN217 for the treatment of multiple myeloma, triggering a
$50 millionmilestone payment from AbbVie
- Abstract for HPN424 interim Phase 1 data accepted for presentation at ASCO20 Virtual
“Harpoon has made remarkable progress since the beginning of 2020, highlighted by the initiation of clinical development for our third novel TriTAC™ program, HPN217, for the treatment of multiple myeloma,” said
First Quarter 2020 Business Highlights and Other Recent Developments
- In April, Harpoon announced the first patient was dosed with HPN217 in a Phase 1/2 clinical trial focused on relapsed/refractory multiple myeloma (RRMM). HPN217 is covered by a global development and option agreement with AbbVie Inc. (NYSE: ABBV) and treatment of the first patient in the clinical trial has triggered a
$50 millionmilestone payment to Harpoon. HPN217 targets B-cell maturation antigen (BCMA), a well-validated target expressed on multiple myeloma cells. HPN217 is Harpoon’s third product candidate to enter the clinic and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC™) platform designed to recruit a patient’s own immune cells to destroy tumors.
- In April, Harpoon appointed
Andrew R. Robbinsand Joseph S. Bailes, M.D., to its Board of Directors. Among his many achievements, Mr. Robbinsis credited with leading the highly successful U.S.launch of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in BRAF-mutant metastatic melanoma. Dr. Bailesis a medical oncologist with substantial experience in clinical practice, legislation, public policy and advocacy, and for nearly two decades, served in various executive leadership capacities with the American Society of Clinical Oncology(ASCO) including as President.
- Patient enrollment and dose escalation continues in the Phase 1 trials for HPN424 in metastatic castration resistant prostate cancer and in the Phase 1/2a trial for HPN536, initially for ovarian and pancreatic cancers. Harpoon plans to present interim HPN424 data at the ASCO 2020 Virtual Meeting (Abstract 5552). The Company will host a virtual event to provide a clinical trial and pipeline update in parallel with the ASCO meeting.
Anticipated 2020 Milestones
- HPN424 – present interim data from the dose escalation phase of our Phase 1 trial at ASCO20 Virtual and initiate expansion cohort in 2020
- HPN536 – present interim data from Phase 1/2a trial in the second half of 2020
- HPN217 – initiate a Phase 1/2 trial in the first half of 2020 (Completed)
- HPN328 – initiate Phase 1/2a trial in the second half of 2020
First Quarter 2020 Financial Results
- Harpoon ended the first quarter of 2020 with
$138.2 millionin cash, cash equivalents, and marketable securities compared to $155.1 millionas of December 31, 2019. This figure does not include the $50 millionmilestone payment achieved through the AbbVie agreement noted above.
- Revenue for the first quarter ended
March 31, 2020was $3.3 millioncompared to $1.1 millionfor the first quarter ended March 31, 2019. The increase in revenue was primarily due to revenue recognized from the upfront payment under the development and option agreement with AbbVie, signed in November 2019.
- Research and development expense for the first quarter ended
March 31, 2020was $12.5 millioncompared to $9.4 millionfor the first quarter ended March 31, 2019. The increase primarily arose from clinical development expenses and an increase in personnel-related expenses, which included conducting preclinical studies, the continuation and preparation of the clinical trials for HPN424, HPN536 and HPN217, and manufacturing activities for four TriTAC product candidates in various stages of development.
- General and administrative expenses for the quarter ended
March 31, 2020was $3.9 millioncompared to $5.8 millionfor the quarter ended March 31, 2019. The decrease was due to higher expenses incurred in the first quarter of 2019 primarily related to legal fees associated with Maverick litigation, and consulting and accounting services, offset by an increase in personnel expenses related to an increase in headcount, and other professional services to support our ongoing operations as a public company.
- Net loss for the quarter ended
March 31, 2020was $12.6 millioncompared to $13.6 millionfor the quarter ended March 31, 2019.
In response to the COVID19 pandemic, Harpoon notes that it closed its executive offices in compliance with county and state shelter-in-place orders, the result of which is that substantially all of the Company’s employees are currently telecommuting, and there is only a limited the number of staff working in the Company’s laboratory. Harpoon is currently continuing its clinical trials it has underway in sites in
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, scope and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of product candidates, the timing of development milestones for product candidates, and the anticipated potential impacts to Harpoon Therapeutics’ business from the ongoing COVID-19 pandemic. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the
Chief Financial Officer
Statement of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
|Three Months Ended
|Collaboration and license revenue||$||3,297||$||1,063|
|Research and development||12,519||9,382|
|General and administrative||3,913||5,832|
|Total operating expenses||16,432||15,214|
|Loss from operations||(13,135||)||(14,151||)|
|Other comprehensive loss:|
|Net unrealized gain on marketable securities||430||26.04|
|Net loss per share, basic and diluted||$||(0.51||)||$||(0.92||)|
|Weighted-average shares used in computing net loss per share, basic and diluted||24,825,367||14,750,260|
Selected Balance Sheet Data
|Cash, cash equivalents, and marketable securities||$||138,240||$||155,129|
|Total stockholders' equity||83,294||94,220|
Source: Harpoon Therapeutics